SRI International

N4 Pharma's Nuvec Delivery System Achieves Targeted RNA Delivery to Lung Cancer Cells

- N4 Pharma's Nuvec gene delivery system successfully demonstrated targeted delivery of RNA to non-small cell lung cancer cells in collaboration with SRI International. - The precision targeting was achieved by functionalising Nuvec with molecules that bind to αvβ6 protein, which is highly expressed in epithelial cancers including lung, breast, prostate and pancreatic cancers. - Targeted Nuvec particles showed selective uptake with RNA payloads delivered only by functionalised particles, validating the system as a differentiated delivery platform for RNA therapies. - The breakthrough addresses a major challenge in oncology by potentially enabling more effective treatments with fewer toxic side effects through precise cancer cell targeting.